These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27874853)

  • 1. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines.
    Du L; Tai W; Yang Y; Zhao G; Zhu Q; Sun S; Liu C; Tao X; Tseng CK; Perlman S; Jiang S; Zhou Y; Li F
    Nat Commun; 2016 Nov; 7():13473. PubMed ID: 27874853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
    Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.
    Ma C; Wang L; Tao X; Zhang N; Yang Y; Tseng CK; Li F; Zhou Y; Jiang S; Du L
    Vaccine; 2014 Oct; 32(46):6170-6176. PubMed ID: 25240756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Fc Fusion on Folding and Immunogenicity of Middle East Respiratory Syndrome Coronavirus Spike Protein.
    Chun J; Cho Y; Park KH; Choi H; Cho H; Lee HJ; Jang H; Kim KH; Oh YK; Kim YB
    J Microbiol Biotechnol; 2019 May; 29(5):813-819. PubMed ID: 30982320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
    Zhang N; Channappanavar R; Ma C; Wang L; Tang J; Garron T; Tao X; Tasneem S; Lu L; Tseng CT; Zhou Y; Perlman S; Jiang S; Du L
    Cell Mol Immunol; 2016 Mar; 13(2):180-90. PubMed ID: 25640653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.
    Kato H; Takayama-Ito M; Iizuka-Shiota I; Fukushi S; Posadas-Herrera G; Horiya M; Satoh M; Yoshikawa T; Yamada S; Harada S; Fujii H; Shibamura M; Inagaki T; Morimoto K; Saijo M; Lim CK
    PLoS One; 2019; 14(10):e0223684. PubMed ID: 31589656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
    Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
    J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of candidate vaccine approaches for MERS-CoV.
    Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
    Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model.
    Hashem AM; Algaissi A; Agrawal AS; Al-Amri SS; Alhabbab RY; Sohrab SS; S Almasoud A; Alharbi NK; Peng BH; Russell M; Li X; Tseng CK
    J Infect Dis; 2019 Oct; 220(10):1558-1567. PubMed ID: 30911758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
    Alharbi NK; Padron-Regalado E; Thompson CP; Kupke A; Wells D; Sloan MA; Grehan K; Temperton N; Lambe T; Warimwe G; Becker S; Hill AVS; Gilbert SC
    Vaccine; 2017 Jun; 35(30):3780-3788. PubMed ID: 28579232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MERS-CoV spike protein: Targets for vaccines and therapeutics.
    Wang Q; Wong G; Lu G; Yan J; Gao GF
    Antiviral Res; 2016 Sep; 133():165-77. PubMed ID: 27468951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
    Jiaming L; Yanfeng Y; Yao D; Yawei H; Linlin B; Baoying H; Jinghua Y; Gao GF; Chuan Q; Wenjie T
    Vaccine; 2017 Jan; 35(1):10-18. PubMed ID: 27899228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.
    Wang Y; Tai W; Yang J; Zhao G; Sun S; Tseng CK; Jiang S; Zhou Y; Du L; Gao J
    Hum Vaccin Immunother; 2017 Jul; 13(7):1615-1624. PubMed ID: 28277821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
    Volz A; Kupke A; Song F; Jany S; Fux R; Shams-Eldin H; Schmidt J; Becker C; Eickmann M; Becker S; Sutter G
    J Virol; 2015 Aug; 89(16):8651-6. PubMed ID: 26018172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and immunogenicity assessment of MERS-CoV pre-fusion spike trimeric oligomers as vaccine immunogen.
    Ahuja R; Vishwakarma P; Raj S; Kumar V; Khatri R; Lohiya B; Saxena S; Kaur G; Singh G; Asthana S; Ahmed S; Samal S
    Hum Vaccin Immunother; 2024 Dec; 20(1):2351664. PubMed ID: 38757508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
    Kim MH; Kim HJ; Chang J
    PLoS One; 2019; 14(7):e0220196. PubMed ID: 31329652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
    Coleman CM; Venkataraman T; Liu YV; Glenn GM; Smith GE; Flyer DC; Frieman MB
    Vaccine; 2017 Mar; 35(12):1586-1589. PubMed ID: 28237499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.